Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)
- Award ceiling
- Not stated
- Closes
- Sep 7, 2026
- Last verified
- 2026-10-09
Per-recipient award not stated for city or township governments, county governments, for profit organizations other than small businesses, independent school districts, native american tribal governments (federally recognized), native american tribal organizations (other than federally recognized tribal governments), nonprofits having a 501(c)(3) status with the irs, other than institutions of higher education, nonprofits that do not have a 501(c)(3) status with the irs, other than institutions of higher education, others (see text field entitled "additional information on eligibility" for clarification), private institutions of higher education, public and state controlled institutions of higher education, public housing authorities/indian housing authorities, small businesses, special district governments, state governments, closing Sep 7, 2026.
City or township governmentsCounty governmentsFor profit organizations other than small businessesIndependent school districtsNative American tribal governments (Federally recognized)Native American tribal organizations (other than Federally recognized tribal governments)Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationOthers (see text field entitled "Additional Information on Eligibility" for clarification)Private institutions of higher educationPublic and State controlled institutions of higher educationPublic housing authorities/Indian housing authoritiesSmall businessesSpecial district governmentsState governmentsEducationHealth & Human Services
In one sentence
Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) does not state a per-recipient award amount, open to city or township governments, county governments, for profit organizations other than small businesses, independent…
Record fields
- Program pool (total)
- Not confirmedTotal across all awards in this programme. Not an amount any single applicant can receive.
- Award ceiling (per project)
- Not confirmed
- Award floor
- Not confirmed
- Typical award
- Not confirmed
- Deadline
- Sep 7, 2026
- Deadline type
- Fixed date
- Opens
- Nov 6, 2024
- Status
- Closed
- Eligible entities
- City or township governments · County governments · For profit organizations other than small businesses · Independent school districts · Native American tribal governments (Federally recognized) · Native American tribal organizations (other than Federally recognized tribal governments) · Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education · Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education · Others (see text field entitled "Additional Information on Eligibility" for clarification) · Private institutions of higher education · Public and State controlled institutions of higher education · Public housing authorities/Indian housing authorities · Small businesses · Special district governments · State governments
- Geography
- Not stated
- Matching funds
- No
- Disbursement
- Not confirmed
- Application effort
- Not confirmed
- Use of funds
- assay development for specific biological targets and disease mechanisms · screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches · hit validation, including implementation of secondary assays · hit-to-lead optimization
- Currency
- USD
How much money is available?
Two different figures govern a programme and they are not interchangeable. The programme pool is what the funder has allocated across every award it will make this cycle. The award ceiling is the most one applicant can be granted.
Program pool (total)Across all awards this cycle
Not statedAward ceiling (per project)The most one applicant can receive
Not statedWho can apply?
level
Derived from the source that published this record
entity
City or township governments, County governments, For profit organizations other than small businesses, Independent school districts, Native American tribal governments (Federally recognized), Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Private institutions of higher education
Source field: entity types+5more
, Public and State controlled institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, Special district governments, State governmentsindustry
Source field: industries
use
assay development for specific biological targets and disease mechanisms, hit validation, including implementation of secondary assays, hit-to-lead optimization, screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches
Source field: use of fundssize limit
Not confirmed
Source field: applicant size limitclause text
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government;…
We store the structured fields above. Clause-by-clause text from the guidelines is not connected for this record.When does it close?
Sep 7, 2026ClosedDeadline type Fixed date
What can the money be used for?
4 categorysThe source’s own spending categories, and what is not parsed.
assay development for specific biological targets and disease mechanismsscreen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approacheshit validation, including implementation of secondary assayshit-to-lead optimization
These categories come from the source's own classification. A line-item cost table, where the programme publishes one, lives in the guidelines and is not parsed for this record.
How hard is the application?
1 fieldEffort, match requirement and reimbursement, as the source stated them.
- Application effort
- Not confirmed
- Disbursement
- Not confirmed
- Matching funds
- No
Who has received this funding?
4036 awardsAwards on file for this programme, counted rather than modelled.
4036 prior awards on file for this programme, largest first. Every row comes from the funder's own award listing; nothing here is estimated.
| Recipient | State | Amount | Fiscal year |
|---|---|---|---|
| ENZYME BY DESIGN INC | Not stated | $399,999 | 2020 |
| KUBANDA CRYOTHERAPY | Not stated | $399,999 | 2021 |
| STEMSYNERGY THERAPEUTICS INC | Not stated | $399,999 | 2022 |
| THERANOSTEC INC | Not stated | $399,999 | 2022 |
| WILDFLOWER BIOPHARMA INC | Not stated | $399,999 | 2020 |
| NEONC TECHNOLOGIES HOLDINGS INC. | Not stated | $399,998 | 2025 |
| OLEOLIVE, INC. | Not stated | $399,998 | 2022 |
| VERAMORPH LLC | Not stated | $399,985 | 2025 |
| SEAK THERAPEUTICS, LLC | Not stated | $399,981 | 2025 |
| TRIPILL BIOTECHNOLOGY, CORP. | Not stated | $399,981 | 2024 |
| DUO ONCOLOGY INC. | Not stated | $399,970 | 2024 |
| DEEP CREEK PHARMA LLC | Not stated | $399,968 | 2025 |
| SEAK THERAPEUTICS, LLC | Not stated | $399,964 | 2020 |
| MABSWITCH INC | Not stated | $399,958 | 2023 |
| TRAVERSE BIOTECH II INC | Not stated | $399,955 | 2023 |
| UNIVERSITY OF ILLINOIS | Not stated | $399,931 | 2023 |
| KINARX, INC | Not stated | $399,924 | 2020 |
| BRIACELL THERAPEUTICS CORP | Not stated | $399,918 | 2023 |
| POP BIOTECHNOLOGIES INC | Not stated | $399,917 | 2020 |
| TRITERPENOID THERAPEUTICS INC | Not stated | $399,908 | 2020 |
| ATHNA BIOTECH INC | Not stated | $399,907 | 2022 |
| TEZCAT BIOSCIENCES, INC. | Not stated | $399,877 | 2020 |
| ALTAY THERAPEUTICS, INC | Not stated | $399,869 | 2022 |
| WASHINGTON UNIVERSITY, THE | Not stated | $399,869 | 2021 |
| GEORGETOWN UNIVERSITY | Not stated | $399,830 | 2020 |
| THE REGENTS OF THE UNIVERSITY OF COLORADO | Not stated | $399,830 | 2020 |
| UNIVERSITY OF WASHINGTON | Not stated | $399,830 | 2024 |
| UNIVERSITY OF WISCONSIN SYSTEM | Not stated | $399,830 | 2025 |
| UNIVERSITY OF WASHINGTON | Not stated | $399,829 | 2024 |
| UNIVERSITY OF WASHINGTON | Not stated | $399,810 | 2020 |
| THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | Not stated | $399,806 | 2020 |
| ONCOSPHERIX INC | Not stated | $399,774 | 2020 |
| RECOMBINATION THERAPEUTICS LLC | Not stated | $399,757 | 2020 |
| PERIOMICS CARE LLC | Not stated | $399,752 | 2020 |
| STRATAGEN BIO, INC. | Not stated | $399,740 | 2021 |
| SHIP OF THESEUS LLC | Not stated | $399,739 | 2025 |
| STRAND THERAPEUTICS INC. | Not stated | $399,725 | 2021 |
| SIEYAX, INC. | Not stated | $399,704 | 2024 |
| THE REGENTS OF THE UNIVERSITY OF COLORADO | Not stated | $399,703 | 2023 |
| IMMUNOBLUE, LLC | Not stated | $399,669 | 2024 |
| CELLCHORUS INC | Not stated | $399,625 | 2025 |
| APEXIMMUNE THERAPEUTICS INC. | Not stated | $399,618 | 2023 |
| VANQUISH BIO LLC | Not stated | $399,580 | 2022 |
| MAYO CLINIC | Not stated | $399,537 | 2023 |
| AQUATEX MEDICAL INC | Not stated | $399,528 | 2023 |
| WASHINGTON UNIVERSITY, THE | Not stated | $399,511 | 2022 |
| TRIO PHARMACEUTICALS, INC | Not stated | $399,478 | 2024 |
| REGENTS OF THE UNIVERSITY OF MICHIGAN | Not stated | $399,450 | 2022 |
| TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | Not stated | $399,446 | 2025 |
| ABILITA THERAPEUTICS INC | Not stated | $399,424 | 2023 |
| NOUS BIOSCIENCES INC | Not stated | $399,373 | 2024 |
| CYTONUS THERAPEUTICS INC. | Not stated | $399,346 | 2020 |
| XAVIER UNIVERSITY OF LOUISIANA | Not stated | $399,320 | 2019 |
| TIBA BIOTECH LLC | Not stated | $399,300 | 2025 |
| PROTON BIO, INC. | Not stated | $399,214 | 2024 |
| AVM BIOTECHNOLOGY, INC. | Not stated | $399,193 | 2022 |
| VIRGINIA COMMONWEALTH UNIVERSITY | Not stated | $399,187 | 2024 |
| VIRGINIA COMMONWEALTH UNIVERSITY | Not stated | $399,186 | 2025 |
| UNIVERSITY OF WISCONSIN SYSTEM | Not stated | $399,185 | 2020 |
| THE JOHNS HOPKINS UNIVERSITY | Not stated | $399,129 | 2025 |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | Not stated | $399,063 | 2021 |
| THE JOHNS HOPKINS UNIVERSITY | Not stated | $399,025 | 2020 |
| IMMUNOGENIK, INC. | Not stated | $398,997 | 2025 |
| IMMUNOGENIK, INC. | Not stated | $398,997 | 2025 |
| THE GENERAL HOSPITAL CORPORATION | Not stated | $398,982 | 2019 |
| LUMINARY THERAPEUTICS, INC. | Not stated | $398,915 | 2024 |
| THE LELAND STANFORD JUNIOR UNIVERSITY | Not stated | $398,911 | 2022 |
| BRIGHAM & WOMENS HOSPITAL INC | Not stated | $398,908 | 2018 |
| AMPEDRNA BIOSCIENCES LLC | Not stated | $398,823 | 2024 |
| NANOMETICS LLC | Not stated | $398,768 | 2021 |
| EMORY UNIVERSITY | Not stated | $398,743 | 2022 |
| MICHIGAN STATE UNIVERSITY | Not stated | $398,743 | 2021 |
| TRIO PHARMACEUTICALS, INC | Not stated | $398,734 | 2022 |
| REGENTS OF THE UNIVERSITY OF MICHIGAN | Not stated | $398,667 | 2020 |
| THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | Not stated | $398,661 | 2019 |
| EMORY UNIVERSITY | Not stated | $398,359 | 2022 |
| MAINEHEALTH | Not stated | $398,304 | 2022 |
| UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | Not stated | $398,291 | 2025 |
| OHIO STATE UNIVERSITY, THE | Not stated | $398,256 | 2020 |
| CLARADELE PHARMACEUTICALS INC | Not stated | $398,242 | 2022 |
| ABACUS BIOSCIENCE INC | Not stated | $398,040 | 2022 |
| KAYOTHERA, INC. | Not stated | $398,040 | 2023 |
| INTRA THERAPEUTICS, LLC | Not stated | $398,039 | 2025 |
| MONON BIOVENTURES LLC | Not stated | $398,018 | 2022 |
| UNIVERSITY OF LOUISVILLE | Not stated | $398,010 | 2022 |
| VIRGINIA COMMONWEALTH UNIVERSITY | Not stated | $397,970 | 2022 |
| MIRIMUS, INC. | Not stated | $397,916 | 2023 |
| THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER | Not stated | $397,651 | 2025 |
| MICROVASCULAR THERAPEUTICS INC | Not stated | $397,597 | 2022 |
| CASE WESTERN RESERVE UNIVERSITY | Not stated | $397,473 | 2019 |
| REGENTS OF THE UNIVERSITY OF MICHIGAN | Not stated | $397,469 | 2022 |
| UNIVERSITY OF CALIFORNIA, LOS ANGELES | Not stated | $397,468 | 2021 |
| THE MEDICAL COLLEGE OF WISCONSIN, INC. | Not stated | $397,467 | 2022 |
| UNIVERSITY OF LOUISVILLE | Not stated | $397,465 | 2024 |
| H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | Not stated | $397,367 | 2019 |
| UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | Not stated | $397,333 | 2021 |
| NEW YORK UNIVERSITY | Not stated | $397,278 | 2019 |
| DNATWO INC | Not stated | $397,221 | 2022 |
| VORTEX BIOTECHNOLOGY CORPORATION | Not stated | $397,168 | 2023 |
| REGENTS OF THE UNIVERSITY OF MINNESOTA | Not stated | $397,033 | 2022 |
Recipient names as published by the California Grants Portal.
What comparable notices state
55 recordsStated ceilings on open records in the same industry.
Among open records stored under Education, 55 of 159 state an award ceiling. Those that do run:
- 25th percentile$172,750
- Median$375,000
- 75th percentile$600,000
A statistical estimate, not a prediction. It describes what a set of notices has published in this catalogue on the day you read it, and says nothing about what this programme will award. Records stating no ceiling are excluded rather than counted as zero, and the programme pool — what a funder has across every applicant — is a different column and is never mixed in.
Who has won this programme before?
4036 awardsAwards under the same assistance listing, not under this notice.
4036 federal awards on file under assistance listing 93.395, the programme this notice is published under. These are not awards made under this notice — a listing covers every year the programme runs, and awards under an open notice do not exist yet.
- $353,109,533PUBLIC HEALTH INSTITUTECA · FY2014
- $138,088,678OREGON HEALTH & SCIENCE UNIVERSITYOR · FY2014
- $135,357,649THE UNIVERSITY OF CHICAGOIL · FY2014
- $125,672,442NRG ONCOLOGY FOUNDATION INCPA · FY2014
- $115,346,605UNIVERSITY OF SOUTHERN CALIFORNIACA · FY2014
Common questions
5 questionsEvery answer is a stored field from this record. Questions the source did not answer are not asked.
- When is the application deadline?
- Sep 7, 2026.
- Who is eligible to apply?
- City or township governments, County governments, For profit organizations other than small businesses, Independent school districts, Native American tribal governments (Federally recognized), Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Others (see text field entitled "Additional Information on Eligibility" for clarification), Private institutions of higher education, Public and State controlled institutions of higher education, Public housing authorities/Indian housing authorities, Small businesses, Special district governments, State governments.
- What can the funding be used for?
- assay development for specific biological targets and disease mechanisms, screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches, hit validation, including implementation of secondary assays, hit-to-lead optimization, as classified by the source.
- Is matching funding required?
- No. The source states that no matching funds are required.
- Has this programme funded anyone before?
- 4036 prior awards are on file for this programme, made by National Institutes of Health. Recipients, amounts and fiscal years are listed on this page.
AI summary of the source text
Optional. Every core field on this record is already above, free and complete.
AI summary of the source text
Studio reads this record’s stored eligibility and materials text and breaks it into separate points, each quoting the exact words it came from. It never writes application prose, never guesses at a field the source did not state, and never estimates anyone’s chances.
Included with Studio
Sign inWhat else is open
Also open from National Institutes of Health
- Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Infrastructure – Clinical Coordinating Center (CCC) & Data Coordinating Center (DCC)Closes Not statedAwards Not stated
- NIH Stroke Clinical Trials Network (StrokeNet) Infrastructure – Regional Coordinating Stroke Centers (RCCs)Closes Not statedAwards Not stated
- Undiagnosed Diseases Network (UDN) Diagnostic Research Innovation CenterCloses Not statedAwards Not stated
- Undiagnosed Diseases Network (UDN) Clinical and Data Coordinating CenterCloses Not statedAwards Not stated
- Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Infrastructure – Clinical Research Sites (U24 Clinical Trial Not Allowed)Closes Not statedAwards Not stated
- Undiagnosed Diseases Network (UDN) Clinical Networks of Diagnostic ExcellenceCloses Not statedAwards Not stated
Also open under assistance listing 93.395
A listing names the programme; a notice names one round of it. These are other rounds open now, not other years of this one.
- Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)Closes Jan 11, 2027Awards up to $700,000
- Forecast to Publish a Notice of Funding Opportunity for SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)Closes Not statedAwards Not stated
- Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)Closes Jan 7, 2027Awards up to $500,000
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)Closes Jan 7, 2027Awards up to $375,000
- Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)Closes Sep 25, 2029Awards Not stated
- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)Closes Jan 7, 2028Awards Not stated
Provenance
Source pagegrants.gov
Retrieved2026-10-09
MethodAutomated check
First seen2026-09-04
Assistance listing93.395
The official page governs. If the source and this record disagree, the source is correct — programmes change their terms between our checks, so confirm every figure above before you apply.